Correlation Between Pasithea Therapeutics and NRX Pharmaceuticals

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Pasithea Therapeutics and NRX Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Pasithea Therapeutics and NRX Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Pasithea Therapeutics Corp and NRX Pharmaceuticals, you can compare the effects of market volatilities on Pasithea Therapeutics and NRX Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Pasithea Therapeutics with a short position of NRX Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of Pasithea Therapeutics and NRX Pharmaceuticals.

Diversification Opportunities for Pasithea Therapeutics and NRX Pharmaceuticals

0.56
  Correlation Coefficient

Very weak diversification

The 3 months correlation between Pasithea and NRX is 0.56. Overlapping area represents the amount of risk that can be diversified away by holding Pasithea Therapeutics Corp and NRX Pharmaceuticals in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on NRX Pharmaceuticals and Pasithea Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Pasithea Therapeutics Corp are associated (or correlated) with NRX Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of NRX Pharmaceuticals has no effect on the direction of Pasithea Therapeutics i.e., Pasithea Therapeutics and NRX Pharmaceuticals go up and down completely randomly.

Pair Corralation between Pasithea Therapeutics and NRX Pharmaceuticals

Given the investment horizon of 90 days Pasithea Therapeutics Corp is expected to under-perform the NRX Pharmaceuticals. In addition to that, Pasithea Therapeutics is 1.36 times more volatile than NRX Pharmaceuticals. It trades about -0.04 of its total potential returns per unit of risk. NRX Pharmaceuticals is currently generating about -0.01 per unit of volatility. If you would invest  161.00  in NRX Pharmaceuticals on September 24, 2024 and sell it today you would lose (19.00) from holding NRX Pharmaceuticals or give up 11.8% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthWeak
Accuracy100.0%
ValuesDaily Returns

Pasithea Therapeutics Corp  vs.  NRX Pharmaceuticals

 Performance 
       Timeline  
Pasithea Therapeutics 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Pasithea Therapeutics Corp has generated negative risk-adjusted returns adding no value to investors with long positions. Despite abnormal performance in the last few months, the Stock's basic indicators remain somewhat strong which may send shares a bit higher in January 2025. The current disturbance may also be a sign of long term up-swing for the company investors.
NRX Pharmaceuticals 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days NRX Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. Even with relatively invariable basic indicators, NRX Pharmaceuticals is not utilizing all of its potentials. The latest stock price agitation, may contribute to short-term losses for the retail investors.

Pasithea Therapeutics and NRX Pharmaceuticals Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Pasithea Therapeutics and NRX Pharmaceuticals

The main advantage of trading using opposite Pasithea Therapeutics and NRX Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Pasithea Therapeutics position performs unexpectedly, NRX Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in NRX Pharmaceuticals will offset losses from the drop in NRX Pharmaceuticals' long position.
The idea behind Pasithea Therapeutics Corp and NRX Pharmaceuticals pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.

Other Complementary Tools

My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
AI Portfolio Architect
Use AI to generate optimal portfolios and find profitable investment opportunities
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Bonds Directory
Find actively traded corporate debentures issued by US companies